Celltrion Inc 068270
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026
-
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
-
Celltrion Shares Rally on U.S. Contract, Earnings Outlook
-
South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility
Trading Information
- Previous Close Price
- ₩190,000.00
- Day Range
- ₩188,400.00–193,300.00
- 52-Week Range
- ₩158,500.00–239,047.62
- Bid/Ask
- ₩188,600.00 / ₩188,600.00
- Shares Outstanding
- 228.02M
- Market Cap
- ₩43.00T
- Volume/Avg
- 11 / 543,436
Key Statistics
- Price/Earnings (Normalized)
- 28.14
- Price/Sales
- 9.01
- Dividend Yield (Trailing)
- 0.38%
- Dividend Yield (Forward)
- 0.38%
- Dividend Payment Schedule
- Apr
- Total Yield
- 1.51%
Company Profile
Celltrion Inc is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company's operating segments include Biopharmaceuticals and Chemical medicine segment. Its Biopharmaceuticals segment includes products and commodities such as biopharmaceutical drugs and related product-support services. The Chemical Medicine segment covers products and commodities including various chemical medicines. It generates the majority of its revenue from the Biopharmaceuticals segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 2,916
- Website
- https://www.celltrion.com
Valuation
|
Metric
|
068270
|
|---|---|
Price/Earnings (Normalized) | 28.14 |
Price/Book Value | 2.46 |
Price/Sales | 9.01 |
Price/Cash Flow | 25.86 |
Price/Earnings
068270
Financial Strength
|
Metric
|
068270
|
|---|---|
Quick Ratio | 0.74 |
Current Ratio | 1.36 |
Interest Coverage | 19.84 |
Quick Ratio
068270
Profitability
|
Metric
|
068270
|
|---|---|
Return on Assets (Normalized) | 6.47% |
Return on Equity (Normalized) | 8.46% |
Return on Invested Capital (Normalized) | 7.21% |
Return on Assets
068270
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#y#TvK< | LOCK|PB@f | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%^@rx&^ | LOCK|H@v& | $83B | |||
| Moderna Inc
MRNA
| LOCK|?<cDV&# | LOCK|gZ | $79B | |||
| argenx SE ADR
ARGX
| LOCK|H##kQd# | LOCK|tD | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|kH@fpJD | LOCK|@Sk | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|rjlJJ% | LOCK|F&Ym& | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|V!^$L^c | LOCK|KyJC$ | $29B | |||
| Incyte Corp
INCY
| LOCK|h@kQ@?^ | LOCK|Q^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|hn!N!MZ | LOCK|Bx | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Xf^Fkq$ | LOCK|gx& | $13B |
United States